10-Q: International Isotopes Inc. Reports First Quarter 2024 Results Amidst Cobalt-57 Shortage

International Isotopes Inc. experienced a slight decrease in revenue and a net loss for the first quarter of 2024, impacted by a global shortage of Cobalt-57 isotopes.

Summary

• International Isotopes Inc. reported a net loss of $154,051 for the three months ended March 31, 2024, compared to a net loss of $148,054 for the same period in 2023.
• The company's revenue decreased by 6% to $2,904,458 in Q1 2024 from $3,089,535 in Q1 2023, primarily due to a decline in Nuclear Medicine Standards revenue.
• Gross profit increased slightly to $1,866,111 in Q1 2024 from $1,780,036 in Q1 2023.
• Operating expenses increased by 11% to $2,132,307 in Q1 2024, driven by higher general, administrative, consulting, and research and development costs.
• The company's Theranostics Products segment saw an 8% increase in revenue, while the Cobalt Products segment experienced a 48% increase.
• The Nuclear Medicine Standards segment experienced a 35% decrease in revenue due to a global shortage of Cobalt-57 isotopes.
• The company's cash and cash equivalents decreased by $319,645 to $2,368,496 as of March 31, 2024.
• Net cash provided by operating activities was $412,444 for the three months ended March 31, 2024, compared to $981,311 for the same period in 2023.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positive growth in certain segments offset by a net loss and revenue decline in others. The company faces supply chain challenges and has a low cash position, which contributes to a negative sentiment. However, the company is taking steps to address these issues and has a plan for the next 12 months.

Positives

• The Theranostics Products segment experienced an 8% increase in revenue, driven by sales of generic sodium iodide I-131 drug product.
• The Cobalt Products segment saw a significant 48% increase in revenue due to the timing of cobalt sealed source manufacturing sales.
• Gross profit increased by 5% to $1,866,111.
• The company is working on an extension to its contract with the DOE for the production of high specific activity cobalt.
• The company has added a supplier for Cobalt-57 isotopes and is searching for additional means to procure critical isotopes.

Negatives

• The company reported a net loss of $154,051 for the quarter.
• Overall revenue decreased by 6% due to a 35% decline in the Nuclear Medicine Standards segment.
• The Nuclear Medicine Standards segment was significantly impacted by a global shortage of Cobalt-57 isotopes.
• Operating expenses increased by 11%, driven by higher general, administrative, consulting, and research and development costs.
• Cash and cash equivalents decreased by $319,645 during the quarter.
• The company anticipates periodic shortages of Cobalt-57 to continue for the remainder of 2024.

Risks

• The company's production of High Specific Activity Cobalt is dependent on the U.S. Department of Energy (DOE) and its prime operating contractor.
• Sales of Theranostics products are dependent on a few key suppliers, and interruptions could negatively impact sales.
• The company's Nuclear Medicine Reference and Calibration Standard products are dependent on radioisotopes from several suppliers, and a loss of any supplier could cause delays or loss of sales.
• The company's future liquidity and capital funding requirements depend on various factors, and there is no assurance that additional capital will be available on acceptable terms.
• The company is subject to the risk of not meeting the terms of the Project Participation Agreement with Lea County, New Mexico, which could result in the loss of the land or the need to purchase it at a cost of $776,078 plus interest.
• The company is subject to the risk of not completing the sale of the Fluorine Products segment assets within the expected timeframe due to various conditions.

Future Outlook

The company expects that cash from operations, equity or debt financing, and its current cash balance will be sufficient to fund operations for the next twelve months. The company anticipates continued sales growth for its Theranostics products, primarily from the sale of its generic sodium iodide I-131 drug product. The company expects a revenue catch-up in the Nuclear Medicine Standards segment upon normalization of the global isotope supply chain. The company expects to close the sale of its Fluorine Products segment assets within 12 to 24 months.

Management Comments

• Management is focused on its strongest long-standing core business segments, including Theranostics Products, Cobalt Products, and Nuclear Medicine Standards.
• Management is pursuing new business opportunities within these core segments.
• Management has begun to focus on the start-up of its Medical Device segment.
• Management considers the NRC license for the de-conversion facility a valuable asset and a significant competitive barrier.

Industry Context

The company operates in the niche market of nuclear medicine and radiopharmaceuticals, facing competition from other suppliers of isotopes and related products. The global shortage of Cobalt-57 isotopes highlights the vulnerability of the supply chain in this industry. The company's focus on its core segments and the development of new products in the medical device segment reflects a strategy to diversify and strengthen its market position. The sale of the Fluorine Products segment assets indicates a strategic shift away from the uranium de-conversion project.

Comparison to Industry Standards

• The company's performance in the Theranostics segment, with an 8% revenue increase, is a positive sign compared to some competitors who may be facing supply chain issues.
• The 48% increase in Cobalt Products revenue is significant, but the volatility of this segment due to large, infrequent sales is a common characteristic in the industry.
• The 35% decrease in Nuclear Medicine Standards revenue due to the Cobalt-57 shortage is a common issue in the industry, with many companies facing similar supply chain disruptions.
• The company's operating expenses increased by 11%, which is higher than some competitors who have been able to control costs more effectively.
• The company's net loss of $154,051 is not unusual for companies in this sector, especially those in a growth phase or facing supply chain challenges. Companies such as Nordion and BWXT Medical also face similar challenges in the nuclear medicine sector.
• The company's cash position of $2,368,496 is relatively low compared to larger players in the industry, which may limit its ability to invest in growth opportunities.

Legal Proceedings

• The company is subject to the terms of the Project Participation Agreement with Lea County, New Mexico, which could result in the loss of the land or the need to purchase it at a cost of $776,078 plus interest.

Related Party Transactions

• The company has promissory notes with its former Chairman of the Board, its Chief Executive Officer and Chairman of the Board, and four major shareholders.

Stakeholder Impact

• Shareholders may be concerned about the net loss and revenue decline, but encouraged by the growth in the Theranostics and Cobalt segments.
• Employees may be affected by the company's financial performance and any potential changes in operations.
• Customers may experience supply chain disruptions due to the global shortage of Cobalt-57 isotopes.
• Suppliers may be impacted by the company's financial performance and any changes in its operations.
• Creditors may be concerned about the company's debt levels and its ability to repay its obligations.

Next Steps

• The company will continue to focus on its core business segments and pursue new business opportunities.
• The company will work on the start-up of its Medical Device segment and the commercialization of its products.
• The company will work on an extension to its contract with the DOE for the production of high specific activity cobalt.
• The company will continue to search for additional means to produce and procure certain critical isotopes.
• The company will work to close the sale of its Fluorine Products segment assets within 12 to 24 months.

Key Dates

Keywords

radioisotopes, nuclear medicine, cobalt-60, cobalt-57, theranostics, medical devices, sodium iodide I-131, calibration standards, radiochemicals, uranium de-conversion